Develops oral small-molecule medicines for chronic diseases, including obesity and related conditions, using a drug-discovery platform focused on GPCR targets.
10-K for FY2025, filed Feb 26, 2026We are a clinical stage global biopharmaceutical company developing novel oral small molecule therapeutics to treat a wide range of chronic…View ↗
Our most advanced product candidate to date is aleniglipron, also known as GSBR-1290, an oral small molecule selective…View ↗
We pursue opportunities to target GPCRs in human diseases on the basis of validated biology, safety, development feasibility and market…View ↗
$35.9M
10-K for FY2025, filed Feb 26, 2026
$35.9M ↗No. It lost $141.2M in FY2025.
10-Q for Q3 FY2026, filed Nov 9, 2026
−$144.8MView ↗
8-K, filed Nov 9, 2026
Phase 3 ACCOMPLISH-1 and ACCOMPLISH-2 registrational clinical trials of aleniglipron (oral small molecule GLP-1 receptor agonist)…View ↗
Competes with Pfizer, Eli Lilly, Qilu Regor Therapeutics, AstraZeneca/Eccogene, Terns Pharmaceuticals, Jiangsu Hengrui Medicine, Huadong, Sciwind Biosciences, Ascletis, Gilead, Kallyope, MindRank, vTv Therapeutics, Carmot Therapeutics, Roche Group, Kailera Therapeutics, Merck, Novo Nordisk, Sanofi, and Boehringer Ingelheim
10-K for FY2025, filed Feb 26, 2026Despite significant biopharmaceutical industry investment, no oral small molecule therapy targeting GLP-1R has been approved for the…View ↗
Loading...